604 related articles for article (PubMed ID: 35012754)
21. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
Iqbal M; Jagadeesh D; Chavez J; Khurana A; Rosenthal A; Craver E; Epperla N; Li Z; Isufi I; Awan FT; Dholaria BR; Maakaron JE; Sandoval-Sus JD; Mishra R; Saha A; Annunzio K; Bhaskar ST; Sumransub N; Fijalka A; Ivanov SA; Lin Y; Kharfan-Dabaja MA
Bone Marrow Transplant; 2024 Feb; 59(2):211-216. PubMed ID: 37973893
[TBL] [Abstract][Full Text] [Related]
22. Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy for Primary and Secondary Central Nervous System Lymphoma: A Systematic Review of Literature.
Asghar N; Masood A; Dhaliwal A; Khurana S; Davis J; Hashmi H; Husnain M
Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):15-21. PubMed ID: 36328891
[TBL] [Abstract][Full Text] [Related]
23. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
24. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
[TBL] [Abstract][Full Text] [Related]
25. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
26. Lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma.
St-Pierre F; Gordon LI
Future Oncol; 2023 Jan; 19(1):19-28. PubMed ID: 36651471
[TBL] [Abstract][Full Text] [Related]
27. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL.
Gauthier J; Gazeau N; Hirayama AV; Hill JA; Wu V; Cearley A; Perkins P; Kirk A; Shadman M; Chow VA; Gopal AK; Hodges Dwinal A; Williamson S; Myers J; Chen A; Nagle S; Hayes-Lattin B; Schachter L; Maloney DG; Turtle CJ; Sorror ML; Maziarz RT
Blood; 2022 Jun; 139(26):3722-3731. PubMed ID: 35439295
[TBL] [Abstract][Full Text] [Related]
28. Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.
Yan ZX; Li L; Wang W; OuYang BS; Cheng S; Wang L; Wu W; Xu PP; Muftuoglu M; Hao M; Yang S; Zhang MC; Zheng Z; Li J; Zhao WL
Clin Cancer Res; 2019 Dec; 25(23):6995-7003. PubMed ID: 31444250
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US.
Oluwole OO; Liu R; Diakite I; Feng C; Patel A; Nourhussein I; Snider JT; Locke FL
J Med Econ; 2022; 25(1):541-551. PubMed ID: 35443867
[TBL] [Abstract][Full Text] [Related]
30. CD19 CAR-T cell therapy for relapsed or refractory diffuse large B cell lymphoma: Why does it fail?
Kinoshita H; Bollard CM; Toner K
Semin Hematol; 2023 Nov; 60(5):329-337. PubMed ID: 38336529
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
32. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199
[TBL] [Abstract][Full Text] [Related]
33. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
Front Immunol; 2021; 12():681984. PubMed ID: 34248965
[TBL] [Abstract][Full Text] [Related]
34. [CAR-T therapy for malignant lymphoma].
Shimoyama T
Rinsho Ketsueki; 2023; 64(11):1447-1455. PubMed ID: 38072433
[TBL] [Abstract][Full Text] [Related]
35. The Implementation of Chimeric Antigen Receptor (CAR) T-cell Therapy in Pediatric Patients: Where Did We Come From, Where Are We Now, and Where are We Going?
Knight E T; Oluwole O; Kitko C
Clin Hematol Int; 2024; 6(1):96-115. PubMed ID: 38817691
[TBL] [Abstract][Full Text] [Related]
36. Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges.
Makita S; Imaizumi K; Kurosawa S; Tobinai K
Drugs Context; 2019; 8():212567. PubMed ID: 30815024
[TBL] [Abstract][Full Text] [Related]
37. Chimeric antigen receptor T-cell therapy-induced nervous system toxicity: a real-world study based on the FDA Adverse Event Reporting System database.
Ren X; Zhang G; Li G; Wang Y
BMC Cancer; 2024 Jan; 24(1):10. PubMed ID: 38166723
[TBL] [Abstract][Full Text] [Related]
38. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.
Onea AS; Jazirehi AR
Am J Cancer Res; 2016; 6(2):403-24. PubMed ID: 27186412
[TBL] [Abstract][Full Text] [Related]
39. Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL.
Roberts ZJ; Better M; Bot A; Roberts MR; Ribas A
Leuk Lymphoma; 2018 Aug; 59(8):1785-1796. PubMed ID: 29058502
[TBL] [Abstract][Full Text] [Related]
40. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial.
Jacobson CA; Chavez JC; Sehgal AR; William BM; Munoz J; Salles G; Munshi PN; Casulo C; Maloney DG; de Vos S; Reshef R; Leslie LA; Yakoub-Agha I; Oluwole OO; Fung HCH; Rosenblatt J; Rossi JM; Goyal L; Plaks V; Yang Y; Vezan R; Avanzi MP; Neelapu SS
Lancet Oncol; 2022 Jan; 23(1):91-103. PubMed ID: 34895487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
